Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance

Historically, the regulatory requirements of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for developing new antibiotics have not addressed pathogen-focused indications for drug approval. The design of the necessary randomized controlled trials traditionally invo...

Descripción completa

Detalles Bibliográficos
Autores principales: Echols, Roger, Ariyasu, Mari, Nagata, Tsutae Den
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853756/
https://www.ncbi.nlm.nih.gov/pubmed/31724048
http://dx.doi.org/10.1093/cid/ciz829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853756/
https://www.ncbi.nlm.nih.gov/pubmed/31724048
http://dx.doi.org/10.1093/cid/ciz829

Ejemplares similares